glp-1 r retatrutide Retatrutide, a GIP, and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Retatrutide (LY3437943) | GCGR/GLP-1R/GIPR Agonist

Patients with complex medical histories, unexplained symptoms, pregnancy considerations, immune disorders, active cancer concerns, severe allergies, medication interactions, or competitive sport obligations should avoid self-directed use and seek medical guidance

Clinicians are faced with untangling many differences in trial design and patient characteristics, and an absence of any direct head-to-head insights

Instead, it provides another potential source of prescription drug coverage for eligible Medicare beneficiaries

Retatrutide at 12mg produced approximately 24% weight loss at 48 weeks compared to tirzepatide at 15mg producing approximately 22% at 72 weeks

Vial users need more

What makes the triple agonist approach so compelling is how it leverages glucagon to increase energy expenditure alongside the appetite suppressing effects of GLP-1 and GIP